Emerging Roles of CAR-T Cell Therapy in Refractory Autoimmune Diseases: A futuristic direction to engineer immune tolerance

Autoimmune diseases are long-term immune-mediated diseases that lead to lack of self-tolerance, continuous inflammation and progressive organ destruction. Despite the revolutionary nature of biologic therapies that have ensured the management of the diseases by addressing particular pathways of inflammation, a significant percentage of patients become refractory or relapse after the withdrawal or necessitate lifelong immunosuppression. Such restrictions have led to efforts to find ways of immune modulation that are more profound and withstand longer. Chimeric antigen receptor T-cell (CAR-T) therapy, which was originally initially developed as a treatment of hematologic malignancies, is becoming a potential immune reprogramming strategy in severe autoimmune diseases. As opposed to normal biologics that inhibit specific inflammatory mediators, CAR-T technology allows specific destruction of autoreactive B-cell groups, which may interfere with pathogenic immune memory and allow immune reset. Initial clinical experience especially in systemic lupus erythematosus can show long-term drug-free remission of specific refractory patients that was obtained after administration of CD19-directed CAR-T therapy. The growing research in the rheumatoid arthritis, multiple sclerosis and myasthenia gravis further indicates the translational aspect of the approach. However, precautionary consideration of the safety, long term immune reconstitution, cost effectiveness and ethical concerns is still critical particularly because autoimmune conditions are not malignant. The next-generation constructs, regulatory CAR-T cells, mRNA-based platforms, and allogeneic products could be improved in the future to increase precision and accessibility. The review is a synthesis of existing mechanistic understanding, clinical data, safety issues, and future opportunities, with CAR-T therapy as a paradigm shifting approach that can potentially alter the current management of autoimmune diseases to be no longer based on chronic suppression but on potential long-term immune re-programming.